Phelps, R., Winston, J. A., Wynn, D., Habek, M., Hartung, H. P., Havrdová, E. K. ... Coles, A. J. (2019). Incidence, management, and outcomes of autoimmune nephropathies following alemtuzumab treatment in patients with multiple sclerosis. Multiple Sclerosis Journal, 25. (9), 1273-1288. doi: 10.1177/1352458519841829
Phelps, Richard, et al. "Incidence, management, and outcomes of autoimmune nephropathies following alemtuzumab treatment in patients with multiple sclerosis." Multiple Sclerosis Journal, vol. 25, br. 9, 2019, str. 1273-1288. https://doi.org/10.1177/1352458519841829
Phelps, Richard, Jonathan A Winston, Daniel Wynn, Mario Habek, Hans Peter Hartung, Eva Kubala Havrdová, Glen S Markowitz, et al. "Incidence, management, and outcomes of autoimmune nephropathies following alemtuzumab treatment in patients with multiple sclerosis." Multiple Sclerosis Journal 25, br. 9 (2019): 1273-1288. https://doi.org/10.1177/1352458519841829
Phelps, R., et al. (2019) 'Incidence, management, and outcomes of autoimmune nephropathies following alemtuzumab treatment in patients with multiple sclerosis', Multiple Sclerosis Journal, 25(9), str. 1273-1288. doi: 10.1177/1352458519841829
Phelps R, Winston JA, Wynn D, Habek M, Hartung HP, Havrdová EK, i sur.. Incidence, management, and outcomes of autoimmune nephropathies following alemtuzumab treatment in patients with multiple sclerosis. Multiple Sclerosis Journal [Internet]. 08.2019. [pristupljeno 30.04.2024.];25(9):1273-1288. doi: 10.1177/1352458519841829
R. Phelps, et al., "Incidence, management, and outcomes of autoimmune nephropathies following alemtuzumab treatment in patients with multiple sclerosis", Multiple Sclerosis Journal, vol. 25, br. 9, str. 1273-1288, Kolovoz 2019. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:105:942822. [Citirano: 30.04.2024.]